Semaglutide – GLP-1 Receptor Agonist for Diabetes and Weight Loss
Semaglutide is an innovative long-acting selective glucagon-like peptide-1 (GLP-1) receptor agonist. As an analogue of the natural human incretin hormone, the drug mimics its biological functions, providing potent regulation of glucose metabolism and energy balance. Semaglutide has become a breakthrough in modern endocrinology due to its ability not only to effectively control diabetes but also to significantly reduce body weight and cardiovascular risks.
The mechanism of action of semaglutide is multifaceted. The drug stimulates glucose-dependent insulin secretion by the pancreas and simultaneously suppresses excessive glucagon secretion, leading to a steady reduction in blood sugar levels without the risk of severe hypoglycemia. Furthermore, semaglutide acts on receptors in the hypothalamus, enhancing the feeling of satiety and suppressing hunger signals, while also slowing gastric emptying. This leads to a significant reduction in calorie intake. Long-term use of the drug contributes to improved lipid profiles, lower blood pressure, and reduced systemic inflammation. A specific modification of the molecule ensures its resistance to enzymatic degradation, allowing for stable plasma concentrations with infrequent administration.
The drug is available in forms for weekly subcutaneous injections or daily oral administration, tailored to individual needs.
Indications
Semaglutide is indicated for adult patients for the long-term treatment of the following metabolic conditions:
- Type 2 Diabetes Mellitus: improvement of glycemic control as monotherapy or in combination with metformin and other hypoglycemic agents.
- Obesity and Overweight: weight management in patients with a BMI ≥30 kg/m² or ≥27 kg/m² in the presence of at least one weight-related comorbidity (hypertension, dyslipidemia).
- Cardiovascular Protection: reduction of the risk of major adverse cardiovascular events (stroke, myocardial infarction) in patients with type 2 diabetes and established cardiovascular disease.
- Complication Prevention: slowing the progression of diabetic nephropathy and maintaining metabolic health in high-risk patients.
Dosage and administration
The semaglutide dosing regimen requires a gradual dose escalation to ensure body adaptation and minimize side effects.
- Injectable Form: the starting dose is 0.25 mg once weekly. After 4 weeks, the dose is increased to 0.5 mg, and if necessary, up to 1.0 mg or 2.0 mg weekly.
- Oral Form: the starting dose is 3 mg daily, with subsequent increases to 7 mg or 14 mg daily every 30 days.
- Administration Method: injections are performed subcutaneously in the abdomen, thigh, or upper arm. Tablets must be taken strictly on an empty stomach 30 minutes before food, with a small amount of water.
- Missed Dose: if an injection is missed, it should be administered within 5 days. If a tablet is missed, the next dose is taken at the usual time the following day.
- Special Notes: dose adjustment in elderly patients or those with renal impairment is usually not required.
